Sign up
Pharma Capital

Collagen Solutions unveils ‘promising data’ for its spray adhesive

Collagen presented a poster at the Society for Biomaterials annual meeting in Minneapolis over the weekend
doctor wrapping a patient's ankle with bandage
Medical industry professionals from around the world meet at the event to present and discuss research

Collagen Solutions PLC (LON:COS) has unveiled some “promising” data for its collagen-based wound healing spray adhesive.

The AIM-listed firm presented a poster at the recent Society for Biomaterials (SFB) annual meeting in Minneapolis which highlighted the new data.

The surgical spray encourages the growth of skin cells and blood vessels in large wounds. At the moment, a sizable skin graft is often required to help heal these type of wounds. Collagen believes that by using the spray as well, a smaller amount of donor skin is required.

Get the best of Proactive delivered straight to your inbox by signing up for our daily newsletter

 “The expansion of this research project and the presentation of additional data in Minneapolis shows continued promise for the possible applications of our fibrillar collagen, and is part of our broader strategy to develop innovative finished devices,” said Collagen chief executive Jamal Rushdy.

“In particular, this novel mechanism for autologous cell delivery via a fibrillar collagen-based spray has the potential to address current shortcomings of products that serve the US$3.8bn global regenerative wound healing market.”

Collagen has been targeting the potentially lucrative wound healing product market recently.

Only last week it signed a development and manufacturing agreement with Smart Matrix with which it will look to develop an advanced wound care scaffold.

Shares were unchanged in early deals at 5p.

View full COS profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.